Navigation Links
Pharmaxis Long-Term Safety Study of Bronchitol Completes
Date:6/11/2008

SYDNEY, Australia, June 11 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the 12 month Phase III clinical trial evaluating the safety of Bronchitol in 100 subjects with bronchiectasis has completed.

This 12-month treatment period was an open label extension to a three- month efficacy trial which has already reported, showing that Bronchitol improved quality of life and mucus clearance. The objective of the open label extension is to determine the adverse event profile of Bronchitol following prolonged use.

Following statistical analysis, the results from this second phase of the trial will be reported in July 2008.

Pharmaxis CEO Alan Robertson said following receipt of the study report, Pharmaxis intends filing its first marketing application in Australia for Bronchitol next quarter.

''We are receiving strong demand to continue treatment after participation in the trial has concluded and, where possible, we make this available.''

Bronchitol is being developed as a twice daily inhalation therapy for people with the incurable lung condition bronchiectasis.

It is estimated that more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for this patient group in 20 years, addressing an important medical need. Total U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disorder; and an increased overall cost to the US health system of US$630 million.

Bronchiectasis is an incurable, degenerative and chronic lung condition that makes breathing difficult through excessive mucus build up in the lungs.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... Roche announced today that a,comp... perceived pain and,discomfort associated with bl...e monitoring systems and lancing devices were deem... overall, the ACCU-CHEK Aviva and ACCU-CHEK Compac...CCU-CHEK Multiclix, ACCU-CHEK,Softclix and ACCU-C...
(Date:12/1/2008)..., Dec. 1 Genaera Corpor...g of subjects has begun in study MSI-1436C-102 (St...dy of trodusquemine (MSI-1436) in overweight and o...utic for the treatment of type 2 diabetes and obes...late insulin and leptin pathways through the highl...
(Date:12/1/2008)...Newswire-FirstCall/ -- Vical Incorporated (Nasdaq:...llion milestone payment from Merck & Co., Inc....clinical trial of an investigational plasmid DNA (...ed on Vical,s DNA gene delivery technology and enc...). hTERT is the subject of separate license agreem...
(Date:11/28/2008)... Eli Lilly and Company,...Drug Application (sNDA) from,the U.S. Food and Dr...e HCl),for the management of chronic pain. Lilly ...lf of 2009, adding data from a recently completed ...the knee. , The decision does not affect du...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 722 1ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 722 2Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 1Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 2Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 3Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 4Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 5Norditropin 28R 29 Approved for Treatment of Children with Short Stature Associated with Turner Syndrome 343 6Multiple corticosteroid injections in pregnant women may increase cerebral palsy 1712 1Multiple corticosteroid injections in pregnant women may increase cerebral palsy 1712 2Is there really a mommy gene in women 3F 1708 1Is there really a mommy gene in women 3F 1708 2
...007 /PRNewswire-FirstCall/ --,SuperGen, Inc. today...ficer, will present at the C.E. Unterberg, Towbin ...ay, July 12, 2007 at the Mandarin,Oriental Hotel i...C.E. Unterberg, Towbin Emerging,Growth Opportuniti...DT. A live webcast of the presentation will be ava...
...07 /PRNewswire-FirstCall/ -- Micromet,Inc. , a bi...t of,novel, proprietary antibody-based products fo...day announced that Dr. Christian Itin,President a...,present at the 3rd Annual C.E. Unterberg, Towbin ..., July 12, 2007 at 10:00am,eastern. , A webcast o...
Other Medicine Technology:SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin,Emerging Growth Conference 2
(Date:12/1/2008)...all/ -- ViroPharma Incorporated,(Nasdaq: VPHM )...lemental,Biologics License Application (sBLA) to ...inryze(TM) C1 Inhibitor (human) as a treatment for... The sBLA is based on a re-analysis and resu...atment study of Cinryze and interim data from an o...
(Date:12/1/2008)...lnesses common, study shows , , MONDAY,...are common among young adults in the United States... To reach this finding, U.S. researchers analyzed ...25, who took part in the National Epidemiologic Su...tudy found that 45.8 percent of the 2,188 college ...
(Date:12/1/2008)...er Institute,s cancer registry has found that as m...or incomplete radiation treatment following breast... can lead to worse outcomes. , Dr. Heather Taffe...gues found that among a nationally representative ...ents aged 65 and older, almost 1,300 women experie...
(Date:12/1/2008)...wire/ -- Americans United for Life (AUL) today a...resolution opposing the federal "Freedom of Choice...pt the resolution immediately when they convene th... AUL President & CEO said, "The so-called ,Fre...protects and promotes the abortion industry, sacri...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...the children who are exposed to cats soon after bi...n inflammatory condition that causes the skin// to...nted at the American Thoracic Society Internationa...sed to two or more dogs at home suggested a slight...
...ra have announced that, they are taking preventive...laria from the past three months//. A senior hea...scheduled to visit Tripura to assess the situation...th reports of drug resistance. He also stated tha...
...octors of Sir Sunderlal hospital in the Banaras Hi... strike// for the second consecutive day today to ... the backward castes in the higher education insti...strike, the agitating doctors formed human chain o...
... was said that 44 % of women suffer from Intimate ...affects both the mental health as well as the phys...d by senior investigators of the Group Health Cent...nalyzed 3,400 women members. The researchers found...
Other Medicine News:Health News:Children Having An Early Exposure To Cats May Develop Eczema 2
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: